Bioretec Ltd's Half-year report 2025: Strong support for future growth from a successful rights issue
TAMPERE, Finland, Aug. 14, 2025 /PRNewswire/ -- Bioretec Ltd Company announcement 14 August 2025 at 8.00 am EEST
This company announcement is a summary of Bioretec Ltd's half-year report for January–June 2025. The complete half-year report with tables is attached to this release as a pdf file and available at the company's web pages at https://investors.bioretec.com/en/reports_and_presentations. The half-year report is unaudited.
April–June 2025 in brief
Bioretec successfully closed a funding round of EUR 9 million, demonstrating investor confidence in the company.
Activa sales developed as expected, with growth particularly in China and Asia, while momentum for RemeOsTM sales builds globally.
First surgeries performed with RemeOs Trauma Screw in Europe mark another key event supporting the commercialization of RemeOs product line worldwide.
Net sales decreased by 51.7% and amounted to EUR 665 thousand (4–6/2024: EUR 1,379 thousand). The net sales was impacted by a one-time credit invoice related to the conclusion of a U.S. pilot distribution agreement, and a shift from stocking to direct distribution partners in the U.S.. Furthermore, the comparison period included a high initial delivery to a new distributor outside the U.S. Sales to stocking distributors are lumpy and may cause quarterly variance in net sales.
Sales margin (excl. other income) was EUR 194 (1,033) thousand, or 29.1% (74.9%) of net sales. Sales margin reflects preparation for commercial growth and was impacted by an increase in materials and services costs related to the shift in distribution partners, as well as the lower margin of sales to China. Sales margin during the market development and scale-up phases is planned to improve as sales increase and direct distribution channel partners are well established.
Profit (loss) for the reporting period was EUR -3,504 (-787) thousand. The cost of the rights issue financing round arranged in June 2025 amounted to EUR 1,065 thousand.
Earnings per share (undiluted) were EUR -0.12 (-0.04).
January–June 2025 in brief
Net sales amounted to EUR 2,062 thousand (1–6/2024: EUR 2,061 thousand).
Sales margin (excl. other income) was EUR 1,016 (1,451) thousand or 49.3% (70.4%) of net sales. The sales margin includes other income of EUR 202 (71) thousand accrued relating to received grants.
Profit (loss) for the reporting period was EUR -4,801 (-1,884) thousand.
Earnings per share (undiluted) were EUR -0.16 (-0.09).
Key figures
EUR 1,000
4–6/2025
4–6/2024
Change, %
1–6/2025
1–6/2024
Change, %
1–12/2024
Net sales
665
1,379
-51.7 %
2,062
2,061
0.0 %
4,544
Sales margin
297
1,045
-71.6 %
1,218
1,523
-20.0 %
3,391
Sales margin (excl. other income)
194
1,033
-81.2 %
1,016
1,451
-22.9 %
3,221
Sales margin, % of net sales
44.6 %
75.7 %
59.1 %
73.9 %
74.6 %
Sales margin% ...
